Skip to Main Content

Paper Details

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.
Invest New Drugs
74
2017
Author NameAffiliation
Stephen Welch
Li LiuM. D. Anderson Cancer Center
  • 1 - 2

Datasets

Release 1.2